Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of a Single 20 mg Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine With or Without Aura

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Evaluating the Efficacy and Safety of a Single 20 mg Dose of Sumatriptan Powder Delivered Intranasally With the Bi-directional Device in Adults With Acute Migraine With or Without Aura

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 26 Sep 2016

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sumatriptan (Primary)
  • Indications Migraine with aura; Migraine without aura
  • Focus Registrational; Therapeutic Use
  • Acronyms TARGET
  • Sponsors OptiNose

Most Recent Events

  • 09 Jun 2016 According to Avanir media release, results will be presented at the 58th American Headache Society Annual Scientific Meeting.
  • 15 Apr 2016 According to an Avanir Pharmaceuticals media release, efficacy analysis from this trial will be presented at the 68th American Academy of Neurology (AAN) Annual Meeting.
  • 28 Jan 2016 According to an OptiNose media release, the US FDA has approved sumatriptan nasal powder (ONZETRA Xsail; AVP-825) for the acute treatment of migraine with or without aura in adults.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top